FIELD: medicine.
SUBSTANCE: invention describes a diagnostic technique for the stages of advanced ovarian carcinoma, involving blood plasma analysis, wherein the patient's disease is staged by the International Federation of Gynaecology and Obstetrics (FIGO) staging system and referred to the clinical stage III or IV as shown by blood plasma protein oxidative modification (POM); stage III is shown by the POM level falling within the range of 4.638 to ∞, while stage IV - by the POM level from 0 to 4.638.
EFFECT: specifying the stages of advanced ovarian carcinoma by the International Federation of Gynaecology and Obstetrics (FIGO) staging system.
8 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CERVICAL CANCER STAGING METHOD | 2016 |
|
RU2645111C2 |
| METHOD OF UPDATING STAGE OF ADVANCED CERVICAL CANCER | 2015 |
|
RU2582979C1 |
| DIFFERENTIAL DIAGNOSTIC TECHNIQUE FOR UTERINE CANCER | 2012 |
|
RU2488823C1 |
| METHOD FOR DIFFERENTIAL DIAGNOSIS OF CERVICAL INTRAEPITHELIAL NEOPLASIA OF GRADE III AND MICROINVASIVE CERVICAL CANCER ASSOCIATED WITH HUMAN PAPILLOMA VIRUS | 2019 |
|
RU2735660C1 |
| METHOD FOR PREDICTION OF PROBABILITY OF POSSIBLE EXECUTION OF OPTIMUM CYTOREDUCTIVE OPERATION IN PATIENTS WITH DISSEMINATED FORMS OF OVARIAN CANCER | 2017 |
|
RU2637399C1 |
| METHOD FOR DIAGNOSIS OF METASTASES TO LYMPH NODES OF SMALL PELVIS IN PATIENTS WITH RESECTABLE CERVICAL CANCER | 2020 |
|
RU2750769C2 |
| METHOD FOR PREDICTING THE OUTCOME OF OVARIAN CANCER FOLLOWING ADJUVANT CHEMOTHERAPY ACCORDING TO THE AP | 2018 |
|
RU2699561C1 |
| METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY CANCER TISSUE GLUTATHIONE REDUCTASE ACTIVITY TEST | 2012 |
|
RU2483304C1 |
| METHOD OF DIFFERENTIAL DIAGNOSTICS OF IRON DEFICIENCY IN PATIENTS WITH OVARIAN CANCER | 2023 |
|
RU2800104C2 |
| METHOD OF DIAGNOSING STAGES I-II OF HIGH-GRADE SEROUS OVARIAN CANCER USING THE LIPID PROFILE OF BLOOD SERUM | 2022 |
|
RU2807396C1 |
